Forming a medicines pricing policy for low and middle-income countries (LMICs): the case for Pakistan

Research output: Contribution to journalArticlepeer-review

Abstract

Equitable access to medicines has played a vital role to improve patient health outcomes and reducing mortality globally. However, it is important to note that medicines pricing is a key determinant in promoting access to medicines. The studies and empirical data have shown that there are wide variations in prices across countries for the same brand of medicines. World Health Organisation (WHO) has provided guidelines to formulate country pharmaceutical pricing policies. However, little is known how these guidelines will be used in the country-specific setting. This commentary provides guiding principles and outlines the basis to form a medicines pricing policy in a low and middle-income country, Pakistan. It discusses the current medicines pricing policy and provides suggestions for future work. The suggested medicines pricing structure and lessons learned in this commentary can also be applied in other low-resource settings.
Original languageEnglish
Article number9
Number of pages6
JournalJournal of Pharmaceutical Policy and Practice
Volume15
Issue number1
DOIs
Publication statusPublished - 24 Feb 2022

Fingerprint

Dive into the research topics of 'Forming a medicines pricing policy for low and middle-income countries (LMICs): the case for Pakistan'. Together they form a unique fingerprint.

Cite this